🔗 Share this article

As America continues making unprecedented changes to its vaccine recommendations, a particular individual appears in a surprising turn: Høeg, an American of Danish descent sports physician and public health researcher who initially gained attention by questioning Covid shots during the global health crisis and has concentrated on potential deaths following COVID-19 immunization in her recent position at the Food and Drug Administration.

Scheduled Shifts to Childhood Immunization Program

Public health authorities were set to reveal major revisions to the pediatric vaccine schedule recently, aligning the US with Denmark’s immunization schedule, it is understood – a substantial departure that would place the US out of alignment with many the world with no evidence for benefit. The announcement has been postponed until the new year.

In place of the director of the vaccine center, Tracy Beth Høeg is listed to present at the gathering. She was recently named interim head of the FDA’s CDER, the fifth individual to run the center this calendar year.

Consolidating Power at the Regulatory Body

This interim role could signify a closer partnership between the drug and biologics centers as Dr. Høeg and Prasad consolidate power at the regulatory agency – and it suggests a greater focus upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has often pushed for ending some pediatric vaccine recommendations in the US so as to align more like Denmark, a society with comprehensive healthcare and a population roughly the population of Wisconsin’s.

So far statements, she has continued to focus on immunizations – typically the responsibility of Dr. Prasad, chief of the FDA’s CBER – as opposed to medication approval.

Concerns Over Expertise

Dr. Høeg has little discernible experience in pharmaceutical research, regulation or management, which has been typical for previous heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the FDA chief and CBER since March.

“It seems she lacks to have the requisite experience” for running the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She is not versed in managing a sizeable institution. She has no expertise in pharmaceutical oversight.”

Former commissioners of CBER would “be deeply familiar with laws and regulations and the underlying principles of pharmaceutical innovation”, noted a former acting FDA commissioner. “Objectively, she lacks the sort of resume that prior appointees who led CBER have had.”

The drug center has an immense portfolio at the agency, she emphasized.

“Many people just pays attention on the novel medication approvals, but the generic drug division clears thousands of off-brand pharmaceuticals. There is also a biosimilars program, non-prescription drug unit and more, and every single one need to be looked after,” Woodcock said. “The thing you overlook, that is precisely what that I always told people is going to cause problems.”

Furthermore, a significant leadership component to the job, which manages in excess of 5,000 staff members. “It is a massive administrative position, if you perform it correctly,” she concluded.

Response and Disputed Policies

Regarding questions about Høeg’s fitness for the role and whether this selection signifies increased cooperation among regulatory chiefs on immunizations, a representative said that the “inquiries are based on inaccurate assumptions”.

“Her experience aligns with the functions of her role,” the spokesperson stated, pointing to the period Dr. Høeg spent advising the FDA commissioner on “medication safety and oversight research, including computational safety modeling and shot safety tracking”.

As acting director, Dr. Høeg takes over the commissioner’s new fast-track approval initiative, a contentious expedited medication authorization process that allegedly worried her preceding directors. “How are these drugs being selected for this fast-track system? Who makes the decisions?” Dr. Howard asked. “There’s a lot of secrecy happening at the regulatory body right now.”

Overall, he stated, “the agency seems to be moving towards less stringent regulations of pharmaceuticals, with the exception of vaccines.”

Documented History on Vaccines

Concerning immunizations, Dr. Høeg has a clearer, if problematic, track record, critics said. She authored a research paper using non-validated crowd-sourced reports to determine the incidence of heart inflammation following Covid vaccination. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who was said to have altered data to imply COVID-19 vaccines are riskier than they are.

Included in her “wish list” for the new government included altering guidelines for new vaccines and ending “unnecessary” immunizations, she said after the election on a podcast. At the agency, Høeg has according to sources proposed barring teenage boys from getting COVID-19 vaccinations.

“She is an complete true believer who starts off with her beliefs and works backwards to accommodate the data in a highly disingenuous, fraudulent way,” Howard argued.

Taking Control and a “Campaign of Retribution”

Dr. Høeg aligned with fellow dissenters, {like|